Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Cancer. 2015 May 29;121(17):3010–3017. doi: 10.1002/cncr.29472

Table 4.

Assocation between CSM and BMI and covariates

Variable HR 95% CI p-value
BMI, continuous(kg/m2) 1.15 1.07–1.23 <0.001
Gleason Score
7 vs 6 3.15 0.48–14.65 0.143
8–10 vs 6 2.59 0.42–15.98 0.304
T-stage
T2 vs T1c 6.29 1.90–20.80 0.003
T3/4 vs T1c 6.47 1.16–36.08 0.033
Log iPSA(ng/mL) 2.41 1.29–4.50 0.006
Age(years) 1.06 0.99–1.14 0.089
ADT Use(yes vs no) 1.25 0.37–4.27 0.722

DM, distant metastasis; CSM, cause-specific mortality; OM, overall mortality; BMI, body mass index; HR, hazard ratio; ADT, androgen deprivation therapy; iPSA, pre-treatment prostate specific antigen.